You’re studying the net version of STAT’s Well being Tech publication, our information to how know-how is reworking the life sciences. Signal as much as get it delivered in your inbox each Tuesday and Thursday.
Good morning well being tech readers!
Right this moment, many well being tech offers.
Attain me: [email protected]
Regeneron well being tech offers: 23andMe and Viz.ai
Regeneron has been busy, with two well being tech offers introduced this week: One is about genetic knowledge and one about AI. Each of them are about growing and promoting medication, actually.
On Monday, the corporate introduced it has agreed to purchase client genetics agency 23andMe out of chapter for $256 million, STAT’s Matthew Herper reports. Regeneron pledged to element its meant use of buyer knowledge to a court-appointed official “and different events.” The corporate hopes to make use of 23andMe’s large trove of genetic knowledge to assist develop new medication, an ambition that 23andMe by no means pulled off.
And this morning, Viz.ai introduced it will associate with Regeneron and Sanofi on an “AI-powered workflow answer” for continual obstructive pulmonary illness. The drugmakers will help Viz.ai’s improvement of a “care acceleration” product that can scan medical data with pure language processing to assist determine high-risk COPD sufferers for potential follow-up.
By the way, Regeneron and Sanofi are working collectively on the event of the antibody itepekimab for the therapy of COPD, they usually count on to submit the drug for approval this yr, in accordance with Sanofi’s pipeline web site. The 2 firms additionally associate on the blockbuster Dupixent, which was just lately permitted to deal with COPD. The press launch for the brand new Viz.ai partnership makes no point out of medication.
This isn’t Viz.ai’s first go-around with drug builders. A couple of years in the past, I reported concerning the firm’s work with Bristol Myers Squibb on AI to assist detection for hypertrophic cardiomyopathy, a coronary heart situation that BMS makes a drug for and could also be key to its future.
Commure’s authorized hassle and new EHR
From STAT’s Brittany Trang: Late final month, well being care security know-how firm Cover obtained a authorized injunction towards Common Catalyst- and Sequoia-backed Commure, barring it from promoting or promoting Commure’s Strongline Professional medical employee duress badges till litigation between the businesses is resolved. Commure was a former Cover buyer that the corporate alleges violated the phrases of its license and copied Cover’s tech. At a Commure occasion in San Francisco final week, Peter Rodrigues, a VP of gross sales on the firm, instructed me he thought the problem could be resolved quickly.
Commure, which has purchased a number of well being tech firms, together with Augmedix, Athelas, and Memora, has a big suite of merchandise for income cycle administration, distant affected person monitoring, ambient documentation, and extra. Government medical director Jean-Luc Neptune instructed me its RCM clients just like the product a lot they requested for a Commure EHR, so a few weeks in the past, Athelas launched one known as Air. The software program is reside in 20 well being techniques proper now and might be in 50 to 60 by the tip of the yr, Commure and Athelas chief know-how officer Dhruv Parthasarathy instructed me.
Denied by AI and different Summit highlights
STAT’s AI-focused Breakthrough Summit West final week was a smash. A couple of tales to focus on from the occasion:
Notable fundraises: Cohere, Sprinter, Akido
- Cohere Well being, which makes software program to assist with prior authorization and different well being plan wants, raised a $90 million sequence C spherical led by Temasek. Deerfield Administration, Outline Ventures, Flare Capital Companions, Longitude Capital, and Polaris Companions additionally invested.
- Residence well being care firm Sprinter Well being raised a $55 million sequence B spherical led by Common Catalyst with participation from Andreessen Horowitz and others.
- Akido, which is growing AI to assist in care supply, raised a $60 million sequence B spherical led by Oak HC/FT.
Odds and ends: Microsoft, Woebot, Google, Oracle
- Microsoft detailed a “healthcare agent orchestrator” at its Construct Developer convention. Stanford Drugs used the product to sew collectively brokers in hopes of bettering most cancers care.
- Woebot just lately instructed customers it will shut down its client app on the finish of June, but when there’s hassle brewing on the firm, founder Alison Darcy didn’t let on throughout an interview at TED 2025 in April.
- Oracle Well being, Cleveland Clinic, and G42 introduced plans “to develop a groundbreaking AI-based healthcare supply platform.”
- Google is hiring a machine studying scientist for its client well being analysis workforce.
What we’re studying
- UnitedHealth’s Optum engaged on Medicare threat scoring system that will use AI, STAT
- Why Apple nonetheless hasn’t cracked AI, Bloomberg Businessweek
